Skip to main navigation

Jump to navigation

Home
  • About
    • Mission and Values
    • Leadership Team
    • Board of Directors
    • Medical Advisors
  • Focus
    • Hyperoxaluria
    • Hyperuricemia
    • Publications
  • Products
    • ALLN-177
    • ALLN-346
    • Pipeline
    • FAQs
  • Investors
    • Overview
    • News Releases
    • In the News
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Shareholder Services
  • Careers
  • Contact
  1. Home ›
  2. Investors

News Releases

News Releases

  • All News
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All News
  • 25
  • 50
  • December 5, 2015

    Summary ToggleAllena Pharmaceuticals Raises $53 Million in Series C Financing

    • Read more
  • November 12, 2015

    Summary ToggleAllena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week

    • Read more
  • November 4, 2015

    Summary ToggleAllena Pharmaceuticals To Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015

    • Read more
  • August 4, 2015

    Summary ToggleAllena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria

    • Read more
  • April 16, 2015

    Summary ToggleAllena Pharmaceuticals Appoints Louis Brenner, M.D. as Chief Operating Officer

    • Read more
  • March 18, 2015

    Summary ToggleAllena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria

    • Read more
  • January 8, 2015

    Summary ToggleAllena Pharmaceuticals to Present at 2015 J.P. Morgan Healthcare Conference

    • Read more

Investor Relations

  • Overview
  • News Releases
  • In the News
  • Events and Presentations
  • Stock Information
  • Analyst Coverage
  • Corporate Governance
  • SEC Filings
  • Shareholder Services
  • LinkedIn
  • LinkedIn
  • Privacy Policy
  • Terms of Use
  • Social Media Community Guidelines

©2021 Allena Pharmaceuticals, Inc. All rights reserved.